The Clinical Outcome and Therapeutic Treatment of a Patient with Double Seronegative Myasthenia Gravis

1. F Romi, J.A.Aarli and N.E. Gilhus. Seronegative myasthenia gravis: disease severity and prognosis. European Journal of Neurology 2005; 12: 413-418.10.1111/j.1468-1331.2005.01137.xSearch in Google Scholar

2. A.Vincent, J.Bowen, J.Newsom-Davis and J.McConvillie. Seonegative generalized mysthenia gravis: clinical features, antibodies and their target. Lancet Neurology 2003; 2: 99-106.10.1016/S1474-4422(03)00306-5Search in Google Scholar

3. Pevzner A, Schoser B, Peteres K, et all. Anti-LRP4 autoantibodies in AchR- and MuSK antibody negative myasthenia gravis. J Neurol 2012; 259(3): 427-35.10.1007/s00415-011-6194-721814823Search in Google Scholar

4. Liyanage Y, Hoch W, Beeson D, Vincet A. The agrin/ muscle specific kinase pathway. New target for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002; 25: 4-16.10.1002/mus.121811754179Search in Google Scholar

5. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23: 489-495.10.1097/WCO.0b013e32833cc96820651592Search in Google Scholar

6. Chan et all. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007 36 (5):651-810.1002/mus.2085417654558Search in Google Scholar

7. Nikolić A, Djukić P, Basta I, et all. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis. Clinical Neurol Neurosurg. 2013 115 (4):432-710.1016/j.clineuro.2012.06.01322770539Search in Google Scholar

8. Evoli A, Tonali P, Padua L, et all. Clinical correlates with anti MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304-2311.10.1093/brain/awg22312821509Search in Google Scholar

9. Kim N, Stiegler AL, Cameron TO, et all. LRP 4 is a receptor for agrin and forms a complex with MuSK. Cell 2008; 135:334-342.10.1016/j.cell.2008.10.002293384018848351Search in Google Scholar

10. Baggi F, Andereetta F, Maggi L et all. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 2013; 8:80 (2): 188-9510.1212/WNL.0b013e31827b907b23255823Search in Google Scholar

11. Witoonpanich et all. Electrophysiological and immunological study in myasthenia gravis: diagnostic sensitivity and correlation. Clin Neurophysiol. 2011 122 (9): 1873-710.1016/j.clinph.2011.02.02621419697Search in Google Scholar

12. Leite MI, Jacob S, Viegas S, et all. IgG1 antibodies to acetylcholine receptors in seronegative myasthenia gravis. Brain 2008; 131: 1940-195210.1093/brain/awn092244242618515870Search in Google Scholar

13. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-denssity lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69: 418-422.10.1002/ana.2231221387385Search in Google Scholar

14. Simon-Chazottes D, Tutois S, Kuehn M,et all. Mutations in the gene encoding the low-density lipoprotein LRP4 cause abnormal limb development in the mouse. Genomics 2006; 87: 673-677.10.1016/j.ygeno.2006.01.00716517118Search in Google Scholar

15. Courtney M. Karner, Martin F. Dietrich, Eric B. Johnson, et all. LRP4 regulates initiation of ureteric budding and is crucial for kidney formation of the neuromuscular junction. Development 2010; 133: 4993-500Search in Google Scholar

16. Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparasion of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007;68:609-61110.1212/01.wnl.0000254620.45529.9717310034Search in Google Scholar